Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
Feb 112013
 

The Hygiology Post is presenting information about a company that seems to have much potential to help many people. Both 2012 and 2013 appear to be pivotal years in determining how helpful the patented technologies may actually be for people.

Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; obtained on 02-11-13). As a matter of disclosure : The author continues to be a current shareholder in the company. On the Senesco Technologies web site (https://www.senesco.com/newsitem.php?id=271; retrieved 2-11-13) the most recent Press Release currently on its web site began this way :

2/6/2013

Senesco to Webcast, Live, at RetailInvestorConferences.com on February 7th

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference on the clinical development of SNS01-T

BRIDGEWATER, N.J. (February 6, 2013) – Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB: SNTI) today announced that Leslie J. Browne, Ph.D., CEO & President, will present at RetailInvestorConferences.com.

DATE: February 7, 2013

TIME: 1:00 PM EST

LINK: https://retailinvestorconferences.com/retail_investor_conferences_february2013.html  then click the red Register/Watch Event Now button on the upper right of screen”.

Today, on the yahoo web site (https://finance.yahoo.com/q?s=snti&ql=1; obtained 2-11-13) The following headline appeared : “Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com PR Newswire(Mon 8:00AM EST)”. The article started out in the following way shortly after the headline :

“Company invites individual and institutional investors to log-on to view presentation

NEW YORK, Feb. 11, 2013 /PRNewswire/ — Senesco Technologies, Inc. (SNTI) announced today that their February 7th RetailInvestorConferences.com presentation is now available for on-demand viewing.

LINK:      www.retailinvestorconferences.com > red ‘register/ watch event now’ button

Senesco’s presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the ‘virtual trade booth’ for the next three weeks.”

This author attended the real time virtual conference on 2-6-13.

The presentation included 27 slides. Information included :

Slide Number 3

“Senesco’s Mission To Help Cure Disease and Feed the World

Senesco has a patent-protected technology

Defective cell growth and cell death can cause disease

Products to re-program cell death and survival

Agriculture, sustainable energy and human disease”

Slide Number 4

“A Specialty Pharma Company  with Oncology Focus

Novel technology platform with the potential to change the way cancer is treated

Senesco technology (>90 issued patents) generates multiple novel therapeutic candidates in cancer and inflammation

Senior leadership team with proven experience in drug development and marketed products”

Slide Number 5

“Senesco Value Proposition

SNS01-T is first in class cancer treatment

on-going Phase 1b/2a human clinical trial in multiple myeloma and non-Hodgkin lymphomas

readily modified to target other cancers

Multiple avenues for exclusivity (patents and orphan status)

Billion dollar market opportunity for B-cell cancers alone”

Slide Number 19

“Clinical Trial Status”

Slide Number 20

“Phase 1b/2a B-Cell Cancer Study at Mayo, UAMS, Hackensack UMC, UWV

Design

Open-label, multiple-dose, dose-escalation 0.0125, 0.05, 0.2, 0.375 mg/kg

Relapsed/refractory MM, MCL, DLBCL ? Twice-weekly IV infusions for 6 weeks Endpoints

Safety and tolerability

Pharmacokinetics

Tumor response markers

M protein, % plasma cells

Time to relapse or progression Research Sites

Mayo Clinic, U Arkansas, Hackensack UMC, U West Virginia Phase 1b/2a B-Cell Cancer Study at Mayo, UAMS, Hackensack UMC, UWV”

Slide Number 21

“Phase 1b/2a Interim Results from Cohort 1

Good tolerability and stable disease at lowest dose

3 patients completed at lowest dose (0.0125 mg/kg)

2 patients had stable disease at weeks 3 & 6 with M-protein levels within 25% of baseline (3.6, 3.0 g/dL respectively) at weeks 3 (3.9, 2.8 g/dL) and 6 (4.2, 2.8 g/dL)

1 responder remained stable 4 weeks post dosing

baseline plasma cell percent declined from 70% to 50% (29% reduction), and, 50% to 15% (70% reduction) in patients with stable disease

No drug-related SAEs or dose-limiting toxicities”

Slide Number 22

“Cohort 1 Results Effects in 2 of 3 Patients…

 

…Serum M-protein is a biomarker of disease progression

(Stable disease = within 25% of baseline levels)
(For patient 41-002, the plasma cell level was reduced by 29%)

(For patient 41-002, the plasma cell level was reduced by 70%)”

There was information displayed on slide 22 which could not be copied and pasted by this author. It showed information that included for patient 41-002 the Baseline Plasma Percent was 70 and at week 6 it was 50. It also showed that for patient 42-002 the Baseline Plasma Percent was 50 and at week 6 it was 15. This author believes that there was therefore an error in slide 22 in that

“(For patient 41-002, the plasma cell level was reduced by 70%)” should have actually been “(For patient 42-002, the plasma cell level was reduced by 70%)”.

 

The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.

 

Louis DeCola, Jr.                                    © 2013 The Hygiology Post ®

 

 Leave a Reply

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

(required)

(required)